Therapeutic value of postmastectomy radiation therapy for T1–2 breast cancer with 1–3 positive lymph nodes
- 11 Downloads
Postmastectomy radiation therapy (PMRT) reduces locoregional recurrence (LRR) and breast cancer mortality for node-positive breast cancer, but its indication remains controversial in patients with 1–3 positive lymph nodes.
We retrospectively analyzed LRR and survival rates in T1–2 breast cancer with 1–3 positive lymph nodes according to PMRT. The prognostic factors and the impact of the current standard systemic therapy (early period: 2000–2007 and late period: 2008–2015) were assessed because adjuvant trastuzumab has only been approved in 2008 in Japan.
Between 2000 and 2015, 162 patients with T1–2N1 breast cancer underwent mastectomy, and 32 (19.8%) underwent PMRT. The 5-year LRR rates were 5.3% in the no PMRT group and 0% in the PMRT group (P = 0.272). Meanwhile, the disease-free survival rates were 80.6% in the no PMRT group and 96.6% in the PMRT group (P = 0.095), and the benefit of PMRT was low in the late period. The significant prognostic factors were larger tumor size (T2) and estrogen receptor negativity.
PMRT tended to improve LRR and disease-free survival. The omission of PMRT is carefully determined.
KeywordsBreast cancer Lymph node metastasis Postmastectomy radiation therapy
We thank Ai Shimamoto for data management.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of ethical approval
All human and animal studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All persons gave their informed consent prior to their inclusion in the study. This article does not contain any studies with animals performed by any of the authors.
- 1.NCCN Clinical Practice Guidelines in Oncology Breast Cancer 2017; 2018Google Scholar
- 5.McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 383:2127–2135CrossRefGoogle Scholar
- 9.Sasada S, Shien T, Iwata H (2018) Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan clinical oncology group survey. Breast CancerGoogle Scholar
- 15.Overgaard M, Nielsen HM, Overgaard J (2007) Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82:247–253CrossRefGoogle Scholar
- 17.Matsunuma R, Oguchi M, Fujikane T, Matsuura M, Sakai T, Kimura K et al (2012) Influence of lymphatic invasion on locoregional recurrence following mastectomy: indication for postmastectomy radiotherapy for breast cancer patients with one to three positive nodes. Int J Radiat Oncol Biol Phys 83:845–852CrossRefGoogle Scholar
- 20.Jagsi R, Momoh AO, Qi J, Hamill JB, Billig J, Kim HM et al (2018) Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction. J Natl Cancer Inst 110Google Scholar
- 21.Magill LJ, Robertson FP, Jell G, Mosahebi A, Keshtgar M (2017) Determining the outcomes of post-mastectomy radiation therapy delivered to the definitive implant in patients undergoing one- and two-stage implant-based breast reconstruction: a systematic review and meta-analysis. J Plast Reconstr Aesthet Surg 70:1329–1335CrossRefGoogle Scholar